Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: 180 Life Sciences Corp.

MissionIRNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

KBL Merger Corp. IV (NASDAQ: KBLM) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.

KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

180 Life Sciences Corp. Pursuing Novel Solutions to Inflammatory Illnesses as Merger Nears Completion

180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be … Continue reading

Posted in 180 Life Sciences Corp. | Leave a comment

MissionIRNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’

180 Life Sciences, a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with … Continue reading

Posted in 180 Life Sciences Corp. | Leave a comment